Metal-Ion-Mediated Amyloid- β Aggregation in Alzheimer's Disease: A Mathematical Model of Chelation and Inhibitory
Shantia Yarahmadian1, Yasser Alzahrani2,3, Vaghawan Prasad Ojha4,5
1Department of Mathematics and Statistics, Mississippi State University, Starkville, MS, 39762, USA. syarahmadian@math.msstate.edu.
Abstract:
We develop a novel, comprehensive, and rigorously validated mathematical framework to investigate the kinetics of amyloid- (A ) aggregation in the presence of biologically relevant metal ions, chelating agents, and inhibitor drugs. Building upon and extending existing aggregation models, our approach integrates metal-assisted aggregation, A self-assembly, and therapeutic interventions within a unified and mechanistically consistent formulation. The model captures the microscopic reaction pathways governing A dynamics and explicitly incorporates the catalytic roles of copper, zinc, and iron ions-key contributors to neurotoxic plaque formation in Alzheimer's disease. Distinctively, the framework combines dual therapeutic strategies: (i) metal chelation therapy, which sequesters free metal ions, and (ii) direct inhibition of A aggregation. Numerical simulations across multiple kinetic regimes reveal how these interventions modulate aggregation pathways, both independently and synergistically. To further validate the model, we perform a quantitative comparison with experimental data by reconstructing aggregate morphology distributions and benchmarking them against reported AFM measurements. The model successfully captures key experimental features, including peak structure and metal-dependent heterogeneity, thereby demonstrating its predictive capability. Overall, this work provides an extended and unified modeling platform that advances the quantitative understanding of metal-mediated amyloid aggregation and offers a predictive tool for evaluating and optimizing therapeutic strategies for Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Treatment
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining, normally used to...
Alzheimer Disease ll: Pathophysiology
Ligand-Gated Ion Channel Receptor: Gating Mechanism


